Effectiveness of Hyaluronic Acid in the Regeneration of Infrabony Defects
Launched by UNIVERSITY OF ROMA LA SAPIENZA · Mar 23, 2020
Trial Information
Current as of October 05, 2025
Completed
Keywords
ClinConnect Summary
Intrabony defects associated with periodontal pockets represent a risk factor for periodontitis progression and additional loss of attachment if left untreated.
Over the years, several strategies have been implemented for their surgically reconstruction with the aim of pocket reduction and clinical attachment level gain.
Grafting of intrabony periodontal defects has been used extensively over the years incorporating various materials, including autogenic bone, demineralized allogenic bone, xenogenic and alloplastic materials. Controlled clinical studies have shown a significantly higher g...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patient related:
- • adults aged 18-65 years with periodontal disease
- • sites with infrabony defects and persisting pockets \[probing pocket depth (PPD) ≥ 5 mm and bleeding on probing (BOP)\] at re-evaluation 6 weeks after non-surgical periodontal therapy
- • full-mouth plaque score (FMPS)1 and full-mouth bleeding score (FMBS)2 \< 20% before surgery
- • at least one radiographically detectable infrabony lesion,3
- • good physical health.
- Site-specific:
- • Interproximal angular defects on single-rooted teeth
- • radiographic infrabony component ≥ 3 mm
- • PPD ≥ 6 mm and CAL ≥ 7 mm.
- Exclusion Criteria:
- • relevant medical conditions contraindicating surgical interventions
- • pregnancy or lactation
- • tobacco smoking
- • untreated periodontal conditions
- • any condition associated with poor compliance or failure to maintain good oral hygiene
- • acute infectious lesions in areas intended for surgery
- • teeth with grade 2 or higher mobility
- • restorations or carious lesions on root surfaces that are associated with the intrabony defect.
About University Of Roma La Sapienza
The University of Roma La Sapienza, one of Italy's premier research institutions, is dedicated to advancing medical science and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its extensive expertise in diverse fields, including medicine, biotechnology, and public health, to conduct rigorous and ethically sound research. Committed to fostering educational excellence and promoting groundbreaking discoveries, La Sapienza actively engages in clinical trials that aim to address critical health challenges and contribute to the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Andrea Pilloni, MD,DDS,MS
Study Director
University of Roma La Sapienza
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials